USP 发布阿司匹林双嘧达莫缓释胶囊专论修订公告
USP Revision Bulletin Notice: Aspirin and Dipyridamole Extended-Release Capsules
USP 小分子2专家委员会修订阿司匹林双嘧达莫缓释胶囊专论,新增溶出度检查法3,以容纳溶出条件和限度与现行方法不同的 FDA 批准产品。公告张贴日期为2026年9月25日,官方日期为2026年10月1日,该修订公告将替代当前生效专论。修订同时调整有机杂质项的表格编号,并按试剂条目统一更新试剂引用。
USP 公开修订公告全文(Revision Bulletin Notice)。本页不包含另行提供的 USP-NF 专论/章节全文。 公告内 Posting Date:2026-09-25;公告内 Official Date:2026-10-01(分别保留,生效日不作发布日期)。 文件的拟修订、预期发布等阶段表述以公告原文为准。
Aspirin and Dipyridamole Extended-Release Capsules
Type of Posting Revision Bulletin
Posting Date 25-Sep-2026
Official Date 01-Oct-2026
Expert Committee Small Molecules 2
In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 2 Expert Committee has revised the Aspirin and Dipyridamole Extended-Release Capsules monograph. The
purpose of this revision is to add Dissolution Test 3 to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). The revision also necessitates a change in the table numbering in the test(s) for Organic Impurities . Existing references to reagents have been updated for consistency with the reagent entry.
• Dissolution Test 3 was validated using the Acquity UPLC BEH C18 brand of column with L1 packing. The typical retention times for aspirin and dipyridamole are about 1.5 and 2.4 min, respectively.
The Aspirin and Dipyridamole Extended-Release Capsules Revision Bulletin supersedes the currently official monograph.
Should you have any questions, please contact Brice Wagner, Scientist IV (301-998-6832 or
来源:USP 公开修订公告 · uspnf.com